Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

James Cameron’s ‘Avatar’ Sequel Surpasses $1 Billion In Global Ticket Sales – $DIS $DIA $INVO

By John F. Heerdink, Jr.

As per reports, Disney’s (DIS) Avatar: The Way of Water surpassed $1 billion in worldwide ticket sales after two weeks in theaters. The movie reached the sales milestone faster than the other two 2022 global hits Paramount Global’s Top Gun: Maverick, and Jurassic World: Dominion, from Comcast Corp.’s Universal. The famous sequel is one of the most expensive movies ever made and needs strong sales to reach break even.

Director James Cameron informed it needs to take in $2 billion in ticket sales to make money. The first Avatar made almost $3 billion at the global box office. In the US and Canada, the sequel has crossed $300 million in sales, Disney informed.

Dow 30 Component, The Walt Disney Company (DIS), and its subsidiaries is a diversified worldwide entertainment company that operates in four business segments: Studio Entertainment, Media Networks, Parks and Resorts, and Consumer Products & Interactive Media. To learn more about this Dow 30 Component, The Walt Disney Company (DIS), and to continue to track its progress please visit the Vista Partners Walt Disney Company, Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also provides select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.


Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently. 

INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market

(Read Original Story: Disney’s ‘Avatar’ Sequel Crosses $1 Billion at Global Box Office in Bloomberg)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us